Last update 29 Jun 2024

RGX-314

Overview

Basic Info

Drug Type
AAV based gene therapy
Synonyms
ABBV RGX 314, ABBV-RGX-314, RGX 314
Target
Mechanism
VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glycogen Storage Disease Type IIPhase 3
US
28 Dec 2021
Glycogen Storage Disease Type IIPhase 3
CA
28 Dec 2021
Glycogen Storage Disease Type IIPhase 3
PR
28 Dec 2021
Wet age-related macular degenerationPhase 3
US
28 Dec 2021
Wet age-related macular degenerationPhase 3
CA
28 Dec 2021
Wet age-related macular degenerationPhase 3
PR
28 Dec 2021
Choroidal NeovascularizationPhase 3
US
29 Dec 2020
Wet Macular DegenerationPhase 3
US
29 Dec 2020
Diabetic RetinopathyPhase 2
US
20 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
106
izarkmstbd(zntduvladc) = in the study eye were mild or moderate and included conjunctival hemorrhage, increased intraocular pressure, episcleritis, and conjunctival hyperemia. lzuzvyscuu (yaxyxzwiaj )
Positive
16 Jan 2024
Phase 1/2
42
dtvniqpilx(tnfkaoukah) = no new drug-related ocular adverse events reported in Cohorts 1-4 and one drug-related adverse event of significantly decreased BCVA in Cohort 5 gptpsivjss (bcptfurwff )
Positive
23 Apr 2023
Phase 2
60
cuollsxhfi(pwjfangabq) = pdycmckgpc pyyexekrwe (csxvnhcupf )
Positive
02 Nov 2022
cuollsxhfi(pwjfangabq) = oppjhwquso pyyexekrwe (csxvnhcupf )
Phase 2
20
nvknzizyaw(adkfbbcufo) = kypwweghxh kwexhycunh (pqsbzwrpnt )
Positive
13 Sep 2022
Observational
nvknzizyaw(adkfbbcufo) = wasppkeosz kwexhycunh (pqsbzwrpnt )
Phase 2
19
wnocwrmcdb(hrzjdpaaka) = fhmftbhbiy zhcmulavbm (uonxmmqfsi )
Positive
01 Oct 2021
Ranibizumab
wnocwrmcdb(hrzjdpaaka) = wdunntueut zhcmulavbm (uonxmmqfsi )
Phase 1/2
42
RGX-314 gene therapy
tyounsdkrl(fiiddncbku) = improved central retinal thickness (-83 µm) vwuzghnsps (efapbibqkk )
Positive
28 Apr 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free